

**NOC/c PART III: CONSUMER  
INFORMATION**

**What is a Notice of Compliance with Conditions**

**Replagal shows promising preliminary evidence of efficacy for the treatment of patients with Fabry Disease; however, the optimal individual dose requires further investigation. Studies are underway to evaluate more frequent and/or higher doses of Replagal therapy than used in**

**(NOC/c)?**

An NOC/c is a form of market approval granted to a product on the basis of **promising** evidence of clinical effectiveness following review of the submission by Health Canada.

Products approved under Health Canada's NOC/c policy are intended for the treatment, prevention or diagnosis of a serious, life-threatening or severely debilitating illness. They have demonstrated promising benefit, are of high quality and possess an acceptable safety profile based on a benefit/risk assessment. In addition, they either respond to a serious unmet medical need in Canada or have demonstrated a significant improvement in the benefit/risk profile over existing therapies. Health Canada has provided access to this product on the condition that sponsors carry out additional clinical trials to verify the anticipated benefit within an agreed upon time frame.

**Replagal®**  
agalsidase alfa

This leaflet is part III of a three-part "Product Monograph" published when Replagal was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about Replagal. Contact your doctor or pharmacist if you have any questions about the drug.

**ABOUT THIS MEDICATION**

What the medication is used for:

Replagal is used to treat Fabry Disease. Replagal is intended for long term use. Replagal treatment should initially be supervised by a physician experienced in the management of patients with Fabry Disease or other inherited metabolic diseases; however, infusions can be given in the patient's home.

What it does:

Replagal is used as enzyme replacement therapy when the level of enzyme in the body is lower than normal as in Fabry Disease.

When it should not be used:

If you are allergic (hypersensitive) to agalsidase alfa or any of the other ingredients of Replagal.

What the medicinal ingredient is:

The active substance in Replagal is agalsidase alfa (1mg/mL). Agalsidase alfa is a form of the human enzyme  $\alpha$ -galactosidase A. It is produced by switching on the gene for  $\alpha$ -galactosidase A in cells. The enzyme is then removed from the cells and made into a sterile concentrate for solution for infusion.

What the important nonmedicinal ingredients are:

The other ingredients are polysorbate 20, sodium chloride, sodium hydroxide, sodium phosphate monobasic monohydrate, and water for injections.

What dosage forms it comes in:

1 mg/mL concentrate for solution for infusion

**WARNINGS AND PRECAUTIONS**

**Serious Warnings and Precautions**

Approximately 10% of patients had reactions during or within one hour following infusion of Replagal. Most reactions were mild. The most common symptoms were chills and facial flushing (warmth and redness). These reactions have generally first happened 2-4 months after the start of treatment and decreased over time. Most of the time you can still be given Replagal even if the symptoms occur.

If you experience an allergic side effect following the administration of Replagal, you should immediately contact your doctor.

If symptoms occur during your infusion:

- Your doctor may stop the infusion temporarily (5-10 min) until the symptoms go away and then begin the infusion again.
- Your doctor may also treat the symptoms with other medicines (antihistamines or corticosteroids).

It is possible that treatment with Replagal will make your body produce antibodies. This will not stop Replagal from working and the antibodies are likely to disappear with time.

If severe allergic (anaphylactic-type) reactions occur, immediate discontinuation of the administration of Replagal may be considered and an appropriate treatment will have to be initiated by your doctor.

### INTERACTIONS WITH THIS MEDICATION

Replagal should not be co-administered with chloroquine, amiodarone, benoquin or gentamicin since these substances have the potential to inhibit intracellular  $\alpha$ -galactosidase activity.

### PROPER USE OF THIS MEDICATION

#### Dose:

The dose is an infusion of 0.2 mg for every kg you weigh. This would be about 14 mg or four 5 mL vials (glass bottles) of Replagal for an average size (70 kg) individual. The infusion will be given every other week.

More frequent and/or higher doses are being studied.

#### Overdose:

There is no experience of overdose with Replagal.

### SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Like all medicines, Replagal can have side effects. Most side effects are mild to moderate and include headache, tingling, numbness, tremors, fatigue, change in temperature sensation, increased blood pressure, upset stomach, diarrhea, coughing, sore throat, difficulty sleeping, change in the taste of food, change in smell, difficulty speaking, acne, dry skin and eye problems. About 1 out of 10 patients may have a reaction during or shortly after infusion of Replagal. These effects include

chills and facial flushing (warmth and redness). However some effects may be serious and may need treatment.

### SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

Tell your doctor immediately if you notice any of these effects which may be serious:

- Swelling in your hands, feet, ankles, face, lips, mouth or throat which may cause difficulty in swallowing or breathing
- Fever
- Rash
- Itching

Tell your doctor as soon as possible if you notice any of the following:

- Signs of infection
- Shortness of breath
- Changes in the way your heart beats (for example, if you notice it beating faster)
- Pain or tenderness in chest, muscles or joints
- Light-headedness

If you notice any side effects not mentioned in this leaflet, please inform your doctor.

*This is not a complete list of side effects. For any unexpected effects while taking Replagal, contact your doctor or pharmacist.*

### HOW TO STORE IT

Store at 2 to 8 °C (in a refrigerator).

### **REPORTING SUSPECTED SIDE EFFECTS**

To monitor drug safety, Health Canada collects information on serious and unexpected effects of drugs. If you suspect you have had a serious or unexpected reaction to this drug you may notify Health Canada by:

toll-free telephone: 866-234-2345

toll-free fax 866-678-6789

By email: [cadmp@hc-sc.gc.ca](mailto:cadmp@hc-sc.gc.ca)

By regular mail:

National AR Centre

Marketed Health Products Safety and Effectiveness  
Information Division

Marketed Health Products Directorate

Tunney's Pasture, AL 0701C

Ottawa ON K1A 0K9

***NOTE: Before contacting Health Canada, you should contact your physician or pharmacist.***

### **MORE INFORMATION**

This document plus the full product monograph, prepared for health professionals can be requested by contacting Paladin Labs Inc., at: 1-888-550-6060.

This leaflet was prepared by Shire Human Genetic Therapies, Inc.

Last revised: FEBRUARY 2008